Fiocruz

GemmaBio Secures $34 Million in Funding

Gemma Biotherapeutics (GemmaBio), a new therapeutics company founded by gene therapy pioneer Jim Wilson, recently announced the completion of a $34 million seed funding round to accelerate its groundbreaking gene therapy initiatives.

Topics • Strategy

Opportunities Through Biotechnology

Top-Feature

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

INOSIM GmbH

Predictive Simulation in Pharma Production

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

CHEManager International c/o Wiley-VCH GmbH

Event Sponsorship: Next Generation Batteries and Hydrogen

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Thomson Reuters

Gemma Biotherapeutics